Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive share transactions rather than a financial results report.
Material Changes
The filing details a specific transaction involving Mr. E J Gray, a Person Discharging Managerial Responsibility. On December 18, 2011, 6,078.046 Ordinary shares vested under the GlaxoSmithKline Deferred Investment Award Plan. This represents the vesting of 25% of an award originally made on December 18, 2006.
Outlook, Risks, and Unusual Items
As a transaction notification, the filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. The only financial detail provided is that Mr. Gray will receive a payment of 1,453.75 pence per Ordinary share on January 20, 2012, following the vesting event.
Investor Verification Checklist
- Verify the total number of shares vested (6,078.046) and the vesting date (December 18, 2011).
- Confirm the payment rate of 1,453.75 pence per share and the scheduled payment date of January 20, 2012.
- Review the original award terms from December 18, 2006, to understand the full context of the 25% vesting.
- Note that this filing does not contain consolidated financial performance data for the period.